Loading...
01/10 00:28
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary shows strong financial performance, increased revenue guidance, strategic partnerships, and promising product developments. The Q&A section supports this with positive updates on Cobenfy's commercial progress and strategic partnerships. Although management avoided some questions, the overall sentiment remains positive due to strong growth outlook and strategic initiatives.
Total company sales Approximately $12.2 billion, reflecting strong demand across the business. Global sales of the growth portfolio increased 17% year-over-year, driven primarily by demand across multiple brands, notably the IO portfolio, Reblozyl, Camzyos, and Breyanzi.
Opdivo global sales Approximately $2.5 billion, up 6% year-over-year. Growth driven by continued demand, strong launch in MSI-high colorectal cancer, and share growth in first-line non-small cell lung cancer.
Reblozyl global sales $615 million, reflecting continued strength across MDS-associated anemia indications. U.S. revenue growth up 38%, driven by demand in first-line RS-positive and RS-negative settings and improved therapy duration. Outside the U.S., sales grew 31%, driven by demand in newly launched markets.
Breyanzi global sales $359 million, annualizing over $1 billion. Global sales grew 58%, reflecting strong demand across all indications. U.S. sales were $251 million, growing 45%, driven by growth in large B-cell lymphoma and new indications. Outside the U.S., sales were $109 million, more than doubling due to demand in existing and newly launched markets.
Camzyos global sales $296 million, up 88% year-over-year, reflecting robust demand. U.S. sales were $238 million, up 76%, driven by increasing new patient starts. Outside the U.S., sales growth more than doubled due to launch momentum in multiple markets.
Eliquis global sales $3.7 billion, growing 23% year-over-year, driven by strong demand and favorable impact of Medicare Part D redesign. U.S. sales grew 29%, and ex-U.S. sales grew 11%.
Sotyktu global sales Grew 20% globally. U.S. sales remained consistent with prior year due to demand being offset by higher rebates associated with increased commercial access.
Cobenfy sales $43 million in the quarter and $105 million year-to-date. Sales and weekly total prescriptions continue to grow steadily.
Gross margin Approximately 73%, primarily due to product mix.
Operating expenses Decreased by approximately $100 million to roughly $4.2 billion compared to the same period last year, primarily reflecting savings from ongoing strategic productivity initiatives.
Cash flow from operations About $6.3 billion in the third quarter, with nearly $17 billion in cash, cash equivalents, and marketable securities as of September 30.
Cobenfy: Steady growth with positive feedback from physicians, indicating a meaningful first indication.
Qvantig: Launch is tracking well.
Iberdomide: Phase III EXCALIBER study showed significant improvement in MRD negativity rates for relapsed/refractory multiple myeloma.
Pumitamig: Phase II data presented; pivotal studies initiated for triple-negative breast cancer, colorectal cancer, and gastric cancer.
CD19 NEX-T: Encouraging data in autoimmune diseases like lupus and scleroderma.
Sotyktu: Long-term extension data validates potential in lupus.
Iza-bren: Received breakthrough therapy designation for advanced EGFR-mutated non-small cell lung cancer.
Anti-tau antibody: Granted Fast Track designation for Alzheimer's disease treatment.
Orbital Therapeutics acquisition: Strengthens cell therapy franchise with potential off-the-shelf CAR-T asset OTX-201 and RNA technology platform.
PhiloChem licensing agreement: Exclusive worldwide rights to Onco-ACP3, a potential breakthrough treatment for prostate cancer.
SystImmune partnership: First patient treated in global Phase II/III trial of iza-bren for triple-negative breast cancer.
Cost structure alignment: Ongoing strategic productivity initiatives saved $1 billion in 2025.
Digital technology and AI integration: Efforts to enhance operational efficiency and agility.
Data-rich period: Anticipating data readouts for 7 new molecular entities and 7 life cycle management opportunities in the next 12-24 months.
Long-term growth strategy: Plan to introduce 10 new medicines and 30 life cycle management opportunities by the end of the decade.
Regulatory and Clinical Risks: The company faces potential challenges in obtaining regulatory approvals for its pipeline drugs, as evidenced by the need for positive outcomes in at least two out of three studies for Cobenfy to support regulatory approval. Additionally, the reliance on pivotal readouts and clinical trial results, such as the Phase III EXCALIBER study and others, introduces uncertainty.
Pipeline and R&D Challenges: The company is heavily reliant on its pipeline for future growth, with plans to introduce 10 new medicines and 30 life cycle management opportunities by the end of the decade. Any delays or failures in clinical trials or regulatory processes could significantly impact its growth trajectory.
Market and Competitive Pressures: The company is working to disrupt entrenched prescribing behaviors, such as with Cobenfy, which may face resistance from physicians accustomed to existing treatments. Additionally, competitive pressures in oncology and other therapeutic areas could impact market share and revenue growth.
Supply Chain and Manufacturing Risks: The company’s reliance on a U.S. manufacturing hub for radiopharmaceutical therapies, which have a short shelf life, introduces logistical and operational risks. Any disruptions in this supply chain could impact the timely delivery of treatments.
Financial Risks: The company is managing a significant debt load, with $6.7 billion of a $10 billion debt paydown commitment still outstanding. Additionally, the financial impact of acquired in-process R&D charges and licensing income could affect profitability.
Economic and Operational Risks: The company is undergoing cost restructuring and integrating digital technology and AI to enhance efficiency. However, these initiatives carry execution risks and may not deliver the anticipated efficiencies or agility.
Revenue Guidance: The company has increased its full-year revenue guidance by $750 million at the midpoint to a range of $47.5 billion to $48 billion, reflecting strong performance of the growth portfolio.
Legacy Portfolio Decline: The legacy portfolio is expected to decline approximately 15% to 17% for the year, with Revlimid sales expected to remain at approximately $3 billion.
Gross Margin: Gross margin guidance for the year remains unchanged at approximately 72%.
Operating Expenses: Operating expense guidance remains unchanged at approximately $16.5 billion, reflecting over $1 billion in net savings versus 2024.
OI&E (Other Income and Expense): Annual income is now expected to be approximately $500 million due to higher-than-anticipated royalties, licensing income, and favorable interest income.
Tax Guidance: Full-year tax guidance remains at approximately 18%.
EPS Guidance: The expected EPS range for 2025 has been narrowed to $6.40 to $6.60, with the midpoint unchanged.
Growth Portfolio Performance: The growth portfolio is expected to continue driving strong demand, with products like Opdivo, Reblozyl, Camzyos, and Breyanzi showing robust growth.
Future Data Readouts: The company anticipates data readouts for ADEPT-2 by the end of the year and two additional Cobenfy studies in Alzheimer's disease psychosis next year. Over the next 12 to 24 months, data for 7 new molecular entities and 7 life cycle management opportunities are expected.
Long-Term Growth Potential: By the end of the decade, the company aims to introduce 10 new medicines to the market and at least 30 significant life cycle management opportunities.
Dividend Commitment: We remain committed to returning capital to our shareholders through the dividend.
The earnings call showed mixed signals. Financial performance is stable, with steady revenue and strong cash reserves. However, concerns about operational risks in the DRC, high logistics costs, and regulatory risks temper optimism. The Q&A session reveals ongoing challenges in securing offtake agreements and operational uncertainties. Although strategic partnerships and product launches are positive, the lack of clear guidance in some areas leads to a neutral outlook, with potential fluctuations in stock price remaining within a narrow range.
The earnings call summary shows strong financial performance, increased revenue guidance, strategic partnerships, and promising product developments. The Q&A section supports this with positive updates on Cobenfy's commercial progress and strategic partnerships. Although management avoided some questions, the overall sentiment remains positive due to strong growth outlook and strategic initiatives.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
